Based on the Oncternal Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Oncternal Therapeutics Inc is USD 14.25 over the next 12 months. Oncternal Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Oncternal Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Oncternal Therapeutics Inc’s stock price was USD 8.31. Oncternal Therapeutics Inc’s stock price has changed by -5.19% over the past week, -7.66% over the past month and +34.04% over the last year.
Analyst Ratings
Target Price Action
Rating Action
Analyst
Rating
Price
Date
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Download Confirmation
Premium customers can only download records visible on the current page view, while Platinum customers can download the first 1000 records.
Paid-only feature
CSV downloads are only available for paying customers.
Thank you for Sharing your Stock Targets for ONCT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
